2 news items
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GOSS
7 May 24
.
Research and Development (R&D) Expenses: For the quarter ended March 31, 2024, R&D expenses were $32.4
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
GOSS
6 May 24
. The Group's research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden
- Prev
- 1
- Next